Immunoglobulin Therapy Does Not Reduce Severe Infection Risk in CLL Patients, Study Finds

A recent study published in Blood Advances indicates that immunoglobulin replacement therapy does not significantly lower the risk of severe infections leading to hospitalization in patients with chronic lymphocytic leukemia (CLL). The research suggests that routine use of this treatment may not provide the expected protective benefits against serious infections in this patient group. For access to the full article, subscribers are encouraged to log in or subscribe. Please note that some institutional site licenses may require additional login procedures or registration for sponsored access.